Company profile
Fennec Pharmaceuticals Inc.
NASDAQ: FENC · Healthcare · Biotechnology
PublicHQ Research Triangle Park, NCCIK 0001211583Reports USD
#446 of 1,418 Healthcare companies by revenue34th-percentile growth
EA Score
61CFH 67DQ 62GM 45SS 55
v0.1 · 65/100 weight · provisional
↑ disclosure history, 3-yr revenue growth · ↓ growth stability, revenue growth (YoY)
Methodology →Revenue TTM
$51.0M
Rev growth YoY (TTM)
+65.0%
Net income (FY)
-$9.7M
Employees
35
as of 2026-08-13
Market cap
$410.9M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$44.6M$44.6M2025
Net income-$9.7M-$9.7M2025
Operating income-$6.3M-$6.3M2025
Total assets$70.6M$70.6M2025
Liabilities$35.1M$35.1M2025
Equity$35.5M$35.5M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY21
FY23
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2020
By product
Royalty100%
By geography
Not disclosed.
The read
What is Fennec Pharmaceuticals Inc.’s revenue?
Fennec Pharmaceuticals Inc. booked $44.6M in FY2025 revenue, contracting 6.1% year over year — slower than 66% of Healthcare companies we track, at a -21.8% net margin.
Peers · Healthcare
Protagonist Therapeutics, Inc.57CSepterna Inc51DTriSalus Life Sciences, Inc.44DAquestive Therapeutics, Inc.47DCumberland Pharmaceuticals Inc.70BNew York Health Care, Inc.——Key facts
CEOJeffrey S. Hackman
SectorHealthcare
IndustryBiotechnology
HeadquartersResearch Triangle Park, NC
ExchangeNASDAQ: FENC
Employees35
IPO date2017-09-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.